• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

    6/25/25 6:22:00 PM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email

    STATESVILLE, N.C., June 25, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2025.

    Kewaunee Scientific Corporation (PRNewsFoto/Kewaunee Scientific Corporation)

    Fiscal Year 2025 Fourth Quarter Results

    Sales during the fourth quarter of fiscal year 2025 were $77,148,000, an increase of 36.1% compared to sales of $56,702,000 from the prior year's fourth quarter. Pre-tax earnings for the quarter were $7,149,000 compared to $1,347,000 for the prior year quarter. Net earnings for the quarter were $4,850,000 compared to net earnings of $11,026,000 for the prior year quarter. Diluted earnings per share were $1.63 compared to diluted earnings per share of $3.71 in the prior year quarter. EBITDA1 for the quarter was $9,671,000 compared to $2,265,000 for the prior year quarter.

    The Company's order backlog was $214.6 million on April 30, 2025, a slight decrease from $221.6 million on January 31, 2025, and an increase from $155.6 million on April 30, 2024.

    Prior Year Quarter Non-Recurring Transactions:

    During the fourth quarter of the previous fiscal year, two non-recurring transactions were recorded that impacted reported earnings and EBITDA which management believes should be considered when analyzing our financial results for the two most recent fiscal years. First, the Company successfully annuitized its pension obligation, which had been in a frozen state since 2005. Terminating the pension resulted in a one-time, non-cash expense and reduction to EBITDA in the quarter of $4,019,000 and a corresponding one-time book tax benefit related to the Company's release of accumulated tax benefits of $3,870,000. The second non-recurring adjustment related to the partial release of the Company's valuation allowance, resulting in an additional tax benefit of $6,583,000 being recorded during the fourth quarter of the previous fiscal year.

    Excluding the two non-recurring transactions, prior year fourth quarter adjusted pre-tax earnings were $5,366,000. Prior year adjusted net earnings were $4,592,000 and prior year adjusted diluted earnings per share was $1.55. Prior year adjusted EBITDA was $6,284,000.

    Current Quarter Adjustments for Professional and Other Fees Related to the Nu Aire Transaction, Integration, and Purchase Accounting: 

    Within the fourth quarter of fiscal year 2025, the Company continued to incur costs associated with the acquisition and integration of Nu Aire, Inc. ("Nu Aire") by Kewaunee Scientific Corporation on November 1, 2024. We believe communicating these impacts and reporting adjusted financial metrics for our fourth quarter fiscal year 2025 helps investors better understand our financial performance.

    Acquisition, integration, and purchase accounting costs in the aggregate in the fourth quarter of fiscal year 2025 reduced pre-tax earnings by $1,258,000 and reduced EBITDA by $650,000.

    After adjusting for these costs, adjusted pre-tax earnings for the quarter were $8,407,000 compared to adjusted pre-tax earnings of $5,366,000 for the prior year quarter, an increase of 56.7%. Adjusted net earnings were $5,814,000 compared to adjusted net earnings of $4,592,000 in the prior year quarter. Adjusted EBITDA for the quarter was $10,321,000 compared to Adjusted EBITDA of $6,284,000 in the prior year quarter. Adjusted diluted earnings per share was $1.95 compared to adjusted diluted earnings per share of $1.55 in the prior year quarter. Further details are presented in the Adjusted Consolidated Statement of Operations Reconciliation schedule.

    Fourth Quarter Segment Results and Discussion:

    Domestic Segment - Domestic sales for the quarter were $55,490,000, an increase of 54.7% from sales of $35,859,000 in the prior year quarter. Domestic segment net earnings were $5,099,000 compared to $3,410,000 in the prior year quarter. Domestic segment EBITDA was $8,755,000 compared to $5,506,000 for the prior year quarter. Domestic segment sales and profitability improved versus the prior year's fourth quarter, driven by higher manufacturing volumes than the prior period and the incorporation of Nu Aire's results.

    International Segment - International sales for the quarter were $21,658,000, an increase of 3.9% from sales of $20,843,000 in the prior year quarter. International segment net earnings were $1,607,000 compared to $1,138,000 in the prior year quarter. International segment EBITDA was $2,427,000 compared to $1,734,000 for the prior year quarter. The impact of customer site delays that have been experienced during the fiscal year decreased in the fourth quarter resulting in an increase in deliveries and billings for the quarter.

    Corporate Segment - Corporate segment net loss was ($1,856,000) for the quarter, as compared to net earnings of $6,478,000 in the prior year quarter. Corporate segment EBITDA loss for the quarter was ($1,511,000) compared to corporate segment EBITDA loss of ($4,975,000) for the prior year quarter. As mentioned above, the prior year quarter includes the impact of two non-recurring transactions that increased net earnings in the prior year quarter. Additionally, the current year quarter includes the impacts of professional service and other fees incurred in relation to the acquisition of Nu Aire, Inc., which closed on November 1, 2024, and costs incurred related to Sarbanes-Oxley 404(b) compliance readiness. Excluding these professional and other fees related to the acquisition of Nu Aire, Corporate segment adjusted EBITDA loss for the quarter was ($1,375,000) compared to Corporate segment adjusted EBITDA loss of ($956,000) for the prior year quarter.

    "Kewaunee again delivered another strong quarter, closing out fiscal year 2025 on a high note. Our team continues to embrace the momentum we have generated in the market, delivering on our commitments to our customers, which continues to result in Kewaunee being the preferred supplier of choice for customers looking to furnish laboratory spaces," said Thomas D. Hull, III, Kewaunee's President and Chief Executive Officer. "Our strategy to emphasize investments in our product portfolio and manufacturing assets while strengthening our dealer and distribution relationships continues to drive performance improvement."

    Fiscal Year 2025 Full Year Results

    Sales during fiscal year 2025 were $240,472,000, an increase of 18.0% compared to sales of $203,755,000 from the prior year. Pre-tax earnings for the fiscal year were $14,785,000 compared to pre-tax earnings of $13,119,000 for the prior year. Net earnings for the fiscal year were $11,405,000, compared to net earnings of $18,753,000 for the prior year. Diluted earnings per share was $3.83, as compared to diluted earnings per share of $6.38 in the prior fiscal year. EBITDA for the fiscal year was $21,613,000, compared to $16,646,000 for the prior fiscal year.

    Prior Year Non-Recurring Transactions:

    As discussed in the Company's fourth quarter results above, two non-recurring transactions were recorded in the prior year fourth quarter that impacted reported earnings and EBITDA. Excluding these two non-recurring prior year fourth quarter transactions, adjusted pre-tax earnings for the prior fiscal year were $17,138,000. Prior year adjusted net earnings were $12,319,000 and prior year adjusted diluted earnings per share was $4.19. Adjusted EBITDA for the prior fiscal year was $20,665,000.

    Current Year Adjustments for Professional and Other Fees Related to the Nu Aire Transaction, Integration, and Purchase Accounting:

    Kewaunee successfully completed the acquisition of Nu Aire on November 1, 2024, marking a significant milestone in our strategic growth initiatives. During the fiscal year, the Company incurred costs associated with the acquisition and integration of Nu Aire. Fiscal year results were also impacted by purchase accounting related to the write-up of various assets on Nu Aire's books. We believe that communicating these impacts and reporting adjusted financial metrics helps investors better understand our financial performance.

    Acquisition, integration, and purchase accounting costs in the aggregate for fiscal year 2025 were a $6,042,000 reduction to pre-tax earnings and a $4,915,000 reduction to EBITDA.

    After adjusting for these costs, adjusted pre-tax earnings for the fiscal year was $20,827,000 compared to adjusted pre-tax earnings of $17,138,000 for the prior year, an increase of 21.5%. Adjusted net earnings were $15,992,000 compared to adjusted net earnings of $12,319,000 in the prior year. Adjusted EBITDA for the fiscal year was $26,528,000 compared to Adjusted EBITDA of $20,665,000 in the prior year. Adjusted diluted earnings per share was $5.37 compared to prior year adjusted diluted earnings per share of $4.19. Further details are presented in the Adjusted Consolidated Statement of Operations Reconciliation schedule.

    Fiscal Year Segment Results and Discussion:

    Domestic Segment - Domestic sales for the fiscal year were $179,398,000, an increase of 30.7% from sales of $137,238,000 in the prior year. Domestic segment net earnings were $15,370,000 compared to $11,808,000 in the prior fiscal year. Domestic segment EBITDA was $25,580,000 compared to $19,146,000 for the prior year. Domestic segment sales and profitability improved versus the prior year as a result of higher manufacturing volumes and the incorporation of Nu Aire's results.

    International Segment - International sales for the fiscal year were $61,074,000, a decrease of 8.2% from sales of $66,517,000 in the prior year. International segment net earnings were $2,902,000 compared to $3,055,000 in the prior fiscal year. International segment EBITDA was $4,475,000 compared to $5,715,000 for the prior year. The decrease in International segment profitability year over year was impacted by customer site delays that pushed out the timing of deliveries and billings.

    Corporate Segment - Corporate segment net loss was ($6,867,000) for the fiscal year, as compared to net earnings of $3,890,000 in the prior fiscal year. Corporate segment EBITDA loss for the fiscal year was ($8,442,000) as compared to Corporate segment EBITDA loss of ($8,215,000) for the prior year. As discussed above, the prior year results include the impact of two non-recurring transactions that increased net earnings in the prior fiscal year. Additionally, the current fiscal year includes the impacts of professional service and other fees incurred in relation to the acquisition of Nu Aire and costs incurred related to Sarbanes-Oxley 404(b) compliance readiness. Excluding these professional and other fees related to the acquisition of Nu Aire, Corporate segment adjusted EBITDA loss for the fiscal year was ($5,053,000) compared to Corporate segment adjusted EBITDA loss of ($4,196,000) for the prior year.

    Consolidated Working Capital Discussion:

    Total cash on hand on April 30, 2025 was $17,164,000, as compared to $25,938,000 on April 30, 2024. The decrease in cash was primarily related to the completion of the Nu Aire acquisition, partially offset by overall improved operating performance. Working capital was $64,651,000 on April 30, 2025, as compared to $56,037,000 on April 30, 2024.

    The Company had short-term debt of $4,773,000 as of April 30, 2025, as compared to $3,099,000 on April 30, 2024. Long-term debt was $60,730,000 on April 30, 2025, as compared to $28,479,000 on April 30, 2024. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $26,632,000 of the long-term debt on April 30, 2025 and $28,133,000 of the long-term debt on April 30, 2024. Long-term debt, net of the sale-leaseback transaction, was $34,098,000 on April 30, 2025 as compared to $346,000 on April 30, 2024. The Company's debt-to-equity ratio on April 30, 2025 was 0.99-to-1, as compared to 0.70-to-1 on April 30, 2024. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on April 30, 2025 was 0.57-to-1, as compared to 0.20-to-1 on April 30, 2024.

    "Fiscal year 2025 was marked by exceptional performance from our Kewaunee team," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "The Company delivered excellent financial results and closed the year with a robust and healthy backlog. These results reflect the consistent execution and dedication of our global team. They are also a testament to the valuable support of our channel partners, who bring our solutions to customers across multiple end markets - customers who rely on Kewaunee's portfolio to advance their most critical priorities and create amazing laboratory spaces."

    "While our industry has been facing a period of instability driven by geopolitical uncertainty, unclear tariff policies and ongoing supply chain disruptions, Kewaunee has responded with resilience. Kewaunee's culture is one of preparedness and a bias towards action which has enabled us to thrive in the midst of these uncertainties. We have a high performing culture and our teams view uncertainty as opportunity."

    "We also have the best channel partners in the business, and our collaborative way of working together is producing results in the marketplace as we continue to win our fair share of projects across all markets we serve. This has never been more evident than in the consistent strength of our backlog in recent fiscal years with strength across most end-markets."

    "In November of this past year, Kewaunee took a significant step forward in our growth journey with the acquisition of Nu Aire, Inc., a pioneer in laboratory equipment and biosafety solutions. This move was guided by a clear strategic intent: To bring together two market leaders with complementary strengths, shared values, and a common vision for the future of laboratory innovation. Nu Aire's future is bright and we have never been more excited about the opportunity for Nu Aire to transform the same way Kewaunee has over the past five years."

    "As we look forward, we are not standing still and we expect to continue to grow both organically and inorganically. Our culture will continue to be a powerful force, fueling our ability to adapt, grow, and deliver lasting value for our customers, communities, partners, and shareholders. For business owners who care deeply about their legacy, their team, and the future of their company, Kewaunee offers more than capital - we offer stewardship, continuity, and a partner they can trust for the next chapter."

    1 EBITDA, Adjusted EBITDA, adjusted net earnings, and adjusted net earnings per share are non-GAAP financial measures. See the tables below for a reconciliation of these non-GAAP measures to the most comparable GAAP measures.

     

    EBITDA and Segment EBITDA Reconciliation



    Quarter Ended April 30, 2024



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  3,410



    $                  1,138



    $                  6,478



    $                11,026

    Add/(Less):

















    Interest Expense



    550



    23



    13



    586

    Interest Income



    —



    (211)



    (124)



    (335)

    Income Taxes



    875



    678



    (11,385)



    (9,832)

    Depreciation and Amortization



    671



    106



    43



    820

    EBITDA



    $                  5,506



    $                  1,734



    $                (4,975)



    $                  2,265

    Pension Termination Costs



    —



    —



    4,019



    4,019

    Adjusted EBITDA



    $                  5,506



    $                  1,734



    $                   (956)



    $                  6,284



















    Quarter Ended April 30, 2025



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                  5,099



    $                  1,607



    $                (1,856)



    $                  4,850

    Add/(Less):

















    Interest Expense



    316



    5



    842



    1,163

    Interest Income



    —



    (113)



    (6)



    (119)

    Income Taxes



    1,910



    825



    (533)



    2,202

    Depreciation and Amortization



    1,430



    103



    42



    1,575

    EBITDA



    $                  8,755



    $                  2,427



    $                (1,511)



    $                  9,671

    Professional and Other Fees2



    514



    —



    136



    650

    Adjusted EBITDA



    $                  9,269



    $                  2,427



    $                (1,375)



    $                10,321



















    Fiscal Year to Date April 30, 2024



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                11,808



    $                  3,055



    $                  3,890



    $                18,753

    Add/(Less):

















    Interest Expense



    1,574



    166



    59



    1,799

    Interest Income



    —



    (849)



    (244)



    (1,093)

    Income Taxes



    3,240



    2,935



    (12,113)



    (5,938)

    Depreciation and Amortization



    2,524



    408



    193



    3,125

    EBITDA



    $                19,146



    5,715



    $                (8,215)



    $                16,646

    Pension Termination Costs



    —



    —



    4,019



    4,019

    Adjusted EBITDA



    $                19,146



    $                  5,715



    $                (4,196)



    $                20,665



















     

     

     

    Fiscal Year to Date April 30, 2025



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                15,370



    $                  2,902



    $                (6,867)



    $                11,405

    Add/(Less):

















    Interest Expense



    1,492



    71



    1,651



    3,214

    Interest Income



    (1)



    (550)



    (416)



    (967)

    Income Taxes



    4,553



    1,632



    (2,983)



    3,202

    Depreciation and Amortization



    4,166



    420



    173



    4,759

    EBITDA



    $                25,580



    $                  4,475



    $                (8,442)



    $                21,613

    Professional and Other Fees3



    1,526



    —



    3,389



    4,915

    Adjusted EBITDA



    $                27,106



    $                  4,475



    $                (5,053)



    $                26,528



    2 Professional and other fees incurred during the three months ended April 30, 2025 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024, and related purchase accounting

    3 Professional and other fees incurred during the twelve months ended April 30, 2025 related to the Company's acquisition of Nu Aire and related purchase accounting

     

    Adjusted Consolidated Statement of Operations Reconciliation





    Three Months Ended

    April 30,



    As Reported

    2025

    Professional

    and Other

    Fees4

    Adjusted

    2025

    Adjusted

    2024

    Net sales

    $        77,148

    $              —

    $        77,148

    $        56,702

    Cost of products sold

    53,110

    686

    52,424

    42,062

    Gross profit

    24,038

    686

    24,724

    14,640

    Operating expenses

    15,538

    572

    14,966

    9,082

    Operating profit

    8,500

    1,258

    9,758

    5,558

    Pension expense

    —

    —

    —

    (36)

    Other (expense) income, net

    (188)

    —

    (188)

    430

    Interest expense

    (1,163)

    —

    (1,163)

    (586)

    Profit (loss) before income taxes

    7,149

    1,258

    8,407

    5,366

    Income tax expense (benefit)

    2,202

    294

    2,496

    621

    Net earnings (loss)

    4,947

    964

    5,911

    4,745

    Less: Net earnings attributable to the non-controlling interest

    97

    —

    97

    153

    Net earnings (loss) attributable to Kewaunee Scientific Corporation

    $          4,850

    $           964

    $          5,814

    $          4,592











    Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders









    Basic

    $            1.70

    $          0.34

    $            2.04

    $            1.61

    Diluted

    $            1.63

    $          0.32

    $            1.95

    $            1.55

     



    Twelve Months Ended

    April 30,



    As Reported

    2025

    Professional

    and Other

    Fees5

    Adjusted

    2025

    Adjusted

    2024

    Net sales

    $      240,472

    $              —

    $      240,472

    $      203,755

    Cost of products sold

    171,615

    1,540

    170,075

    151,704

    Gross profit

    68,857

    1,540

    70,397

    52,051

    Operating expenses

    51,098

    4,178

    46,920

    33,770

    Operating profit

    17,759

    5,718

    23,477

    18,281

    Pension expense

    —

    —

    —

    (158)

    Other income, net

    240

    324

    564

    814

    Interest expense

    (3,214)

    —

    (3,214)

    (1,799)

    Profit (loss) before income taxes

    14,785

    6,042

    20,827

    17,138

    Income tax expense (benefit)

    3,202

    1,455

    4,657

    4,515

    Net earnings (loss)

    11,583

    4,587

    16,170

    12,623

    Less: Net earnings attributable to the non-controlling interest

    178

    —

    178

    304

    Net earnings (loss) attributable to Kewaunee Scientific Corporation

    $        11,405

    $         4,587

    $        15,992

    $        12,319











    Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders









    Basic

    $            3.98

    $           1.60

    $            5.59

    $            4.28

    Diluted

    $            3.83

    $           1.54

    $            5.37

    $            4.19



    4 Professional and other fees incurred during the three months ended April 30, 2025 related to the Company's acquisition of Nu Aire and related purchase accounting, including the estimated tax impact

    5 Professional and other fees incurred during the twelve months ended April 30, 2025 related to the Company's acquisition of Nu Aire and related purchase accounting and costs incurred related to the early termination of the Company's Revolving Credit Facility, including the estimated tax impact of both transactions

    About Non-GAAP Measures

    The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the acquisition of Nu Aire, Inc. and the corresponding tax impact in fiscal year 2025 and GAAP net earnings adjusted for net pension settlement expenses and the impact of a valuation allowance release in fiscal year 2024. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

    EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the one-time costs incurred for professional and other fees related to the acquisition of Nu Aire, Inc. during FY25 or the pension termination enacted during FY24, as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization or the costs incurred related to the acquisition of Nu Aire, Inc. during fiscal year 2025 or our one-time pension termination transaction executed during fiscal year 2024, which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.

    About Kewaunee Scientific 

    Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. 

    Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China.

    Learn more at the companies' websites, located at http://www.kewaunee.com  and http://www.nuaire.com/.  

    This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the most recent fiscal year ended April 30, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Kewaunee Scientific Corporation

    Condensed Consolidated Statements of Operations

    ($ and shares in thousands, except per share amounts)





    Three Months Ended

    April 30,



    Twelve Months Ended

    April 30,



    2025



    2024



    2025



    2024

    Net sales

    $         77,148



    $         56,702



    $       240,472



    $       203,755

    Cost of products sold

    53,110



    42,062



    171,615



    151,704

    Gross profit

    24,038



    14,640



    68,857



    52,051

    Operating expenses

    15,538



    9,082



    51,098



    33,770

    Operating profit

    8,500



    5,558



    17,759



    18,281

    Pension expense

    —



    (4,055)



    —



    (4,177)

    Other (expense) income, net

    (188)



    430



    240



    814

    Interest expense

    (1,163)



    (586)



    (3,214)



    (1,799)

    Profit before income taxes

    7,149



    1,347



    14,785



    13,119

    Income tax expense (benefit)

    2,202



    (9,832)



    3,202



    (5,938)

    Net earnings

    4,947



    11,179



    11,583



    19,057

    Less: Net earnings attributable to the non-controlling interest

    97



    153



    178



    304

    Net earnings attributable to Kewaunee Scientific Corporation

    $           4,850



    $         11,026



    $         11,405



    $         18,753

















    Net earnings per share attributable to Kewaunee Scientific Corporation

    stockholders















    Basic

    $             1.70



    $             3.86



    $             3.98



    $             6.51

    Diluted

    $             1.63



    $             3.71



    $             3.83



    $             6.38

    Weighted average number of common shares outstanding















    Basic

    2,854



    2,858



    2,862



    2,879

    Diluted

    2,981



    2,972



    2,979



    2,938

     

    Kewaunee Scientific Corporation

    Condensed Consolidated Balance Sheets

    ($ in thousands)





    April 30, 2025



    April 30, 2024

    Assets







    Cash and cash equivalents

    $           14,942



    $           23,267

    Restricted cash

    2,222



    2,671

    Receivables, less allowances

    62,384



    45,064

    Inventories

    32,849



    20,679

    Prepaid expenses and other current assets

    5,966



    5,136

    Total Current Assets

    118,363



    96,817

    Net Property, Plant and Equipment

    23,174



    17,649

    Right of use assets

    12,965



    7,454

    Deferred income taxes

    3,994



    7,401

    Intangible assets, net

    17,831



    —

    Goodwill

    12,487



    —

    Other assets

    5,840



    5,445

    Total Assets

    $         194,654



    $         134,766









    Liabilities and Stockholders' Equity







    Short-term borrowings

    $                986



    $             3,099

    Current portion of term loan

    2,903



    —

    Current portion of lease obligations

    3,371



    2,234

    Current portion of financing liability

    788



    713

    Accounts payable

    27,033



    23,262

    Other Current Liabilities

    18,631



    11,472

    Total Current Liabilities

    53,712



    40,780

    Long-term portion of lease obligations

    8,946



    5,669

    Long-term portion of financing liability

    26,632



    27,420

    Long-term portion of seller note

    23,537



    —

    Long-term portion of term loan

    10,412



    —

    Other non-current liabilities

    5,170



    4,688

    Total Liabilities

    128,409



    78,557

    Commitments and Contingencies







    Stockholders' Equity:







    Kewaunee Scientific Corporation Equity

    64,457



    54,760

    Non-controlling interest

    1,788



    1,449

    Total Stockholders' Equity

    66,245



    56,209

    Total Liabilities and Stockholders' Equity

    $         194,654



    $         134,766

     

    Contact:

    Donald T. Gardner III



    704/871-3274

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-fiscal-year-and-fourth-quarter-302491500.html

    SOURCE Kewaunee Scientific Corporation

    Get the next $KEQU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2026

    STATESVILLE, N.C., Dec. 10, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2025. Fiscal Year 2026 Second Quarter Results: Sales during the second quarter of fiscal year 2026 were $70,096,000, an increase of 46.8% compared to sales of $47,764,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,453,000 compared to $3,931,000 for the prior year quarter, a decrease of 12.2%. Net earnings were $2,445,000 compared to net earnings of $3,008,000 for the prior year quarte

    12/10/25 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Announces Successful Debt Refinancing and Full Repayment of Seller Notes From the Company's Acquisition of Nu Aire, Inc.

    STATESVILLE, N.C., Dec. 4, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, today announced its successful debt refinancing and the full repayment of its Seller Notes. On December 4, 2025, Kewaunee Scientific Corporation (the "Company" or "Kewaunee") successfully repaid in full and ahead of schedule its Seller Notes, entered into November 1, 2024, in connection with the Company's acquisition of Nu Aire, Inc. ("Nu Aire"). The Seller No

    12/4/25 4:55:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific to Report Results for Second Quarter Fiscal Year 2026

    STATESVILLE, N.C., Nov. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its second quarter fiscal year 2026 financial results on Wednesday, December 10, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's pr

    11/26/25 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gardner Donald T. Iii sold $128,280 worth of shares (3,000 units at $42.76), decreasing direct ownership by 21% to 11,564 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    10/10/25 8:44:28 AM ET
    $KEQU
    Medical Specialities
    Industrials

    VP - Human Resources Phillips Elizabeth D sold $297,219 worth of shares (6,880 units at $43.20), decreasing direct ownership by 45% to 8,248 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    10/2/25 1:36:34 PM ET
    $KEQU
    Medical Specialities
    Industrials

    President, CEO Hull Thomas David Iii sold $43,090 worth of shares (1,000 units at $43.09), decreasing direct ownership by 3% to 38,719 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    10/2/25 9:16:06 AM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    SEC Filings

    View All

    SEC Form 10-Q filed by Kewaunee Scientific Corporation

    10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/12/25 9:41:25 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/10/25 4:09:37 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/4/25 4:59:35 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    4/7/25 10:57:11 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/24/25 4:32:54 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/18/25 3:20:26 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Financials

    Live finance-specific insights

    View All

    Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

    STATESVILLE, N.C., June 25, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2025. Fiscal Year 2025 Fourth Quarter Results Sales during the fourth quarter of fiscal year 2025 were $77,148,000, an increase of 36.1% compared to sales of $56,702,000 from the prior year's fourth quarter. Pre-tax earnings for the quarter were $7,149,000 compared to $1,347,000 for the prior year quarter. Net earnings for the quarter were $4,850,000 compared to net earnings of $11,026,000 for the prio

    6/25/25 6:22:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

    STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

    3/12/25 4:16:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

    STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

    12/11/24 4:04:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Leadership Updates

    Live Leadership Updates

    View All

    Kewaunee Scientific Announces Appointment of J. Jette Campbell to Board of Directors

    STATESVILLE, N.C., Sept. 11, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, announces the appointment of J. Jette Campbell, CPA, to its Board of Directors, effective September 10, 2025. Campbell brings decades of experience guiding organizations through significant growth and transformation. Campbell's impressive career spans leadership roles at global companies such as PepsiCo, Frito-Lay, and Griffin LLC, a DuPont venture. He also

    9/11/25 4:03:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    11/1/24 9:14:13 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 11:44:29 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 9:59:14 AM ET
    $KEQU
    Medical Specialities
    Industrials